Table 1 Baseline characteristics of analysed patients
Characteristic | <65 years (n = 2,126) | 65-75 years (n = 932) | ≥ 75 years (n = 129) | p-valuea |
|---|---|---|---|---|
Males, n (%) | 1,324 (62.3) | 593 (63.6) | 79 (61.2) | 0.74 |
Age at treatment initiation | ||||
Median (min-max) | 57.7 (21.3-64.9) | 68.3 (65.0-74.9) | 76.9 (75.0-85.2) | - |
Localization, n (%) | ||||
Colon | 1,287 (60.5) | 571 (61.3) | 84 (65.1) | 0.57 |
Rectum | 839 (39.5) | 361 (38.7) | 45 (34.9) | |
History of thromboembolism, n (%) | 68 (3.2) | 55 (5.9) | 7 (5.4) | 0.002 |
History of hypertension, n (%) | 629 (29.6) | 494 (53.0) | 85 (65.9) | <0.001 |
Primary metastatic, n (%) | ||||
M0 | 804 (37.8) | 389 (41.7) | 55 (42.6) | 0.09 |
M1 | 1,322 (62.2) | 543 (58.3) | 74 (57.4) | |
Adenocarcinoma, n (%) | 2,060 (96.7) | 916 (98.3) | 127 (98.4) | 0.07 |
Prior surgery, n (%) | 1,690 (79.5) | 808 (86.7) | 117 (90.7) | <0.001 |
Prior radiotherapy, n (%) | 437 (20.6) | 200 (21.5) | 17 (13.2) | 0.09 |
Adjuvant chemotherapy, n (%) | 639 (30.1) | 302 (32.4) | 39 (30.2) | 0.43 |
Site of metastatic disease, n (%) | ||||
Liver | 1,348 (63.4) | 594 (63.7) | 99 (76.7) | 0.009 |
Lung | 504 (23.7) | 240 (25.8) | 31 (24.0) | 0.48 |
Other | 933 (43.9) | 390 (41.8) | 41 (31.8) | 0.02 |
Number of metastatic sites, % | ||||
1/2/>2 | 55.5/31.2/13.3 | 58.6/31.8/9.6 | 62.7/30.2/7.1 | 0.02 |
Chemotherapy regimens, n (%) | ||||
FOLFOX | 903 (42.5) | 394 (42.3) | 51 (39.5) | <0.001 |
XELOX | 753 (35.4) | 313 (33.6) | 25 (19.4) | |
FOLFIRI | 199 (9.4) | 74 (7.9) | 5 (3.9) | |
XELIRI | 127 (6.0) | 39 (4.2) | 1 (0.8) | |
Capecitabine | 39 (1.8) | 44 (4.7) | 18 (14.0) | |
5-FU/LV | 21 (1.0) | 21 (2.3) | 23 (17.8) | |
Other | 67 (3.2) | 32 (3.4) | 3 (2.3) | |
Without CT | 17 (0.8) | 15 (1.6) | 3 (2.3) | |
PS at bevacizumab initiation, n (%) | ||||
0 | 612 (28.8) | 256 (27.5) | 41 (31.8) | 0.02 |
1 | 549 (25.8) | 279 (29.9) | 39 (30.2) | |
2-3 | 24 (1.1) | 15 (1.6) | 6 (4.7) | |
Not available | 941 (44.3) | 382 (41.0) | 43 (33.3) | |
Treatment duration (months) | ||||
Median (min- max) | 7.4 (0.5-58.7) | 6.9 (0.5-41.7) | 6.4 (0.5-31.0) | 0.04 |
Best response, n (%) | ||||
CR | 332 (15.6) | 112 (12.0) | 8 (6.2) | 0.003 |
PR | 675 (31.7) | 271 (29.1) | 40 (31.0) | |
SD | 741 (34.9) | 381 (40.9) | 59 (45.7) | |
PD | 248 (11.7) | 107 (11.5) | 12 (9.3) | |
Not available | 130 (6.1) | 61 (6.5) | 10 (7.8) |